SUMMIT Results: Bezuclastinib in Non-Advanced Systemic Mastocytosis
April 3, 2025 • ISM Content Hub
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights regarding the SUMMIT trial. This is a Phase 2 study designed to evaluate bezuclastinib in non-advanced systemic mastocytosis. Results showed that a daily 100-mg oral dose reduces mast cell burden biomarkers in most patients, and is well tolerated. Improvements in symptom severity and overall well-being were also reported by patients with this treatment.
